Uroxatral (Alfuzosin HCl) Patent Expiration, LOE Window & CMS Spending

Uroxatral (Alfuzosin HCl) by Advanz (Us): Off-Patent Genericized (AB Competition), 4 AB generics, $1.7M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAdvanz (Us)
FDA Application & PathwayN021287 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$1.7M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 21.1% 2-yr change)